Skip to main content
Premium Trial:

Request an Annual Quote

Abbott Licenses Rubicon's Methylation-Detection Tech

NEW YORK (GenomeWeb News) — Abbott has obtained a non-exclusive license to use Rubicon Genomics' MethylPlex methylation-detection technology, which it will use to develop in vitro diagnostics that detect presence or risk of prostate, bladder, and colon cancer, Rubicon said today.

The deal, which was struck as part of an ongoing agreement between the two companies, also grants Abbott a non-exclusive license to use the MethylPlex for screening applications with other diseases, and options to colon cancer biomarkers that it co-developed with Rubicon.

Financial terms of the agreement were not released.

The ongoing collaboration "has been very productive with both parties making significant contributions towards development and commercialization of IVD products that employ MethylPlex biomarkers and assays," Rubicon acting-President and CEO James Koziarz said in a statement.

Filed under

The Scan

Breast Cancer Risk Related to Pathogenic BRCA1 Mutation May Be Modified by Repeats

Several variable number tandem repeats appear to impact breast cancer risk and age at diagnosis in almost 350 individuals carrying a risky Ashkenazi Jewish BRCA1 founder mutation.

Study Explores Animated Digital Message Approach to Communicate Genetic Test Results to Family Members

In the Journal of Genetic Counseling, the approach showed promise in participants presented with a hypothetical scenario related to a familial hereditary breast and ovarian cancer syndrome diagnosis.

Computational Tool Predicts Mammalian Messenger RNA Degradation Rates

A tool called Saluki, trained with mouse and human messenger RNA data, appears to improve mRNA half-life predictions by taking RNA and genetic features into account, a Genome Biology paper reports.

UK Pilot Study Suggests Digital Pathway May Expand BRCA Testing in Breast Cancer

A randomized pilot study in the Journal of Medical Genetics points to similar outcomes for breast cancer patients receiving germline BRCA testing through fully digital or partially digital testing pathways.